Chemistry is an experimental science, and the best way to enjoy it and learn about it is performing experiments. Product Details of 5455-94-7. Introducing a new discovery about 5455-94-7, Name is 2,2,5,5-Tetramethyldihydrofuran-3(2H)-one
LGD1069, 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl] benzoic acid, is the first retinoid X receptor (RXR) selective retinoid to enter clinical trials for treatment of dermatological diseases and cancer. In order to examine biological properties such as receptor binding, metabolism and bioavailability, [13C]-, [14C]-, and [3H]-labeled LGD1069 is required. Herein, we describe synthetic methods for preparing isotopically labeled homologs of LGD 1069 as well as comparative competition binding data for [6,7-3H]-LGD1069 and [3H]-9-cis retinoic acid with RXR active retinoids. The final radiolabeled products, [6,7-3H]-LGD1069 and 3-[14C]-LGD1069 have specific activities of 56 Ci/mmol and 49 mCi/mmol, respectively. Radiochemical purities are 99.5% for [6,7-3H]-LGD1069 and 99.0% for 3-[14C]-LGD1069. The chemical purity is 99.0% for 3-[13CD3]-LGD1069. Competition binding studies with known retinoids show similar K(d) values when either [6,7-3H]-LGD1069 or [3H]-9-cis retinoic acid is used as the radioligand.
Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.Recommanded Product: 5455-94-7, you can also check out more blogs about5455-94-7
Reference:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem